#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0419] By way of further illustration, the precursor material is selected from the group consisting of antithrombogenic agents, antiplatelet agents, prostaglandins, thrombolytic drugs, antiproliferative drugs, antirejection drugs, antimicrobial drugs, growth factors, and anticalcifying agents.
#Text=[0420] By way of yet further illustration, the precursor material may, e.g., be any one or more of the therapeutic agents disclosed in column 5 of U.S.
1-1	0-1	[	_	_	
1-2	1-5	0419	_	_	
1-3	5-6	]	_	_	
1-4	7-9	By	_	_	
1-5	10-13	way	_	_	
1-6	14-16	of	_	_	
1-7	17-24	further	_	_	
1-8	25-37	illustration	_	_	
1-9	37-38	,	_	_	
1-10	39-42	the	_	_	
1-11	43-52	precursor	_	_	
1-12	53-61	material	_	_	
1-13	62-64	is	_	_	
1-14	65-73	selected	_	_	
1-15	74-78	from	_	_	
1-16	79-82	the	_	_	
1-17	83-88	group	_	_	
1-18	89-99	consisting	_	_	
1-19	100-102	of	_	_	
1-20	103-119	antithrombogenic	_	_	
1-21	120-126	agents	_	_	
1-22	126-127	,	_	_	
1-23	128-140	antiplatelet	_	_	
1-24	141-147	agents	_	_	
1-25	147-148	,	_	_	
1-26	149-163	prostaglandins	_	_	
1-27	163-164	,	_	_	
1-28	165-177	thrombolytic	_	_	
1-29	178-183	drugs	_	_	
1-30	183-184	,	_	_	
1-31	185-202	antiproliferative	_	_	
1-32	203-208	drugs	_	_	
1-33	208-209	,	_	_	
1-34	210-223	antirejection	_	_	
1-35	224-229	drugs	_	_	
1-36	229-230	,	_	_	
1-37	231-244	antimicrobial	_	_	
1-38	245-250	drugs	_	_	
1-39	250-251	,	_	_	
1-40	252-258	growth	_	_	
1-41	259-266	factors	_	_	
1-42	266-267	,	_	_	
1-43	268-271	and	_	_	
1-44	272-286	anticalcifying	_	_	
1-45	287-293	agents	_	_	
1-46	293-294	.	_	_	
1-47	295-296	[	_	_	
1-48	296-300	0420	_	_	
1-49	300-301	]	_	_	
1-50	302-304	By	_	_	
1-51	305-308	way	_	_	
1-52	309-311	of	_	_	
1-53	312-315	yet	_	_	
1-54	316-323	further	_	_	
1-55	324-336	illustration	_	_	
1-56	336-337	,	_	_	
1-57	338-341	the	_	_	
1-58	342-351	precursor	_	_	
1-59	352-360	material	_	_	
1-60	361-364	may	_	_	
1-61	364-365	,	_	_	
1-62	366-369	e.g	_	_	
1-63	369-370	.	_	_	
1-64	370-371	,	_	_	
1-65	372-374	be	_	_	
1-66	375-378	any	_	_	
1-67	379-382	one	_	_	
1-68	383-385	or	_	_	
1-69	386-390	more	_	_	
1-70	391-393	of	_	_	
1-71	394-397	the	_	_	
1-72	398-409	therapeutic	_	_	
1-73	410-416	agents	_	_	
1-74	417-426	disclosed	_	_	
1-75	427-429	in	_	_	
1-76	430-436	column	_	_	
1-77	437-438	5	_	_	
1-78	439-441	of	_	_	
1-79	442-445	U.S	_	_	
1-80	445-446	.	_	_	

#Text=Pat.
2-1	447-450	Pat	_	_	
2-2	450-451	.	_	_	

#Text=No. 5,464,650.
3-1	452-454	No	_	_	
3-2	454-455	.	_	_	
3-3	456-465	5,464,650	_	_	
3-4	465-466	.	_	_	

#Text=Thus, and referring to such column 5, "The therapeutic substance used in the present invention could be virtually any therapeutic substance which possesses desirable therapeutic characteristics for application to a blood vessel.
4-1	467-471	Thus	_	_	
4-2	471-472	,	_	_	
4-3	473-476	and	_	_	
4-4	477-486	referring	_	_	
4-5	487-489	to	_	_	
4-6	490-494	such	_	_	
4-7	495-501	column	_	_	
4-8	502-503	5	_	_	
4-9	503-504	,	_	_	
4-10	505-506	"	_	_	
4-11	506-509	The	_	_	
4-12	510-521	therapeutic	_	_	
4-13	522-531	substance	_	_	
4-14	532-536	used	_	_	
4-15	537-539	in	_	_	
4-16	540-543	the	_	_	
4-17	544-551	present	_	_	
4-18	552-561	invention	_	_	
4-19	562-567	could	_	_	
4-20	568-570	be	_	_	
4-21	571-580	virtually	_	_	
4-22	581-584	any	_	_	
4-23	585-596	therapeutic	_	_	
4-24	597-606	substance	_	_	
4-25	607-612	which	_	_	
4-26	613-622	possesses	_	_	
4-27	623-632	desirable	_	_	
4-28	633-644	therapeutic	_	_	
4-29	645-660	characteristics	_	_	
4-30	661-664	for	_	_	
4-31	665-676	application	_	_	
4-32	677-679	to	_	_	
4-33	680-681	a	_	_	
4-34	682-687	blood	_	_	
4-35	688-694	vessel	_	_	
4-36	694-695	.	_	_	

#Text=This can include both solid substances and liquid substances.
5-1	696-700	This	_	_	
5-2	701-704	can	_	_	
5-3	705-712	include	_	_	
5-4	713-717	both	_	_	
5-5	718-723	solid	_	_	
5-6	724-734	substances	_	_	
5-7	735-738	and	_	_	
5-8	739-745	liquid	_	_	
5-9	746-756	substances	_	_	
5-10	756-757	.	_	_	

#Text=For example, glucocorticoids (e.g. dexamethasone, betamethasone), heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, and, more generally, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents could be used.
6-1	758-761	For	_	_	
6-2	762-769	example	_	_	
6-3	769-770	,	_	_	
6-4	771-786	glucocorticoids	_	_	
6-5	787-788	(	_	_	
6-6	788-791	e.g	_	_	
6-7	791-792	.	_	_	
6-8	793-806	dexamethasone	_	_	
6-9	806-807	,	_	_	
6-10	808-821	betamethasone	_	_	
6-11	821-822	)	_	_	
6-12	822-823	,	_	_	
6-13	824-831	heparin	_	_	
6-14	831-832	,	_	_	
6-15	833-840	hirudin	_	_	
6-16	840-841	,	_	_	
6-17	842-852	tocopherol	_	_	
6-18	852-853	,	_	_	
6-19	854-865	angiopeptin	_	_	
6-20	865-866	,	_	_	
6-21	867-874	aspirin	_	_	
6-22	874-875	,	_	_	
6-23	876-879	ACE	_	_	
6-24	880-890	inhibitors	_	_	
6-25	890-891	,	_	_	
6-26	892-898	growth	_	_	
6-27	899-906	factors	_	_	
6-28	906-907	,	_	_	
6-29	908-924	oligonucleotides	_	_	
6-30	924-925	,	_	_	
6-31	926-929	and	_	_	
6-32	929-930	,	_	_	
6-33	931-935	more	_	_	
6-34	936-945	generally	_	_	
6-35	945-946	,	_	_	
6-36	947-959	antiplatelet	_	_	
6-37	960-966	agents	_	_	
6-38	966-967	,	_	_	
6-39	968-981	anticoagulant	_	_	
6-40	982-988	agents	_	_	
6-41	988-989	,	_	_	
6-42	990-1001	antimitotic	_	_	
6-43	1002-1008	agents	_	_	
6-44	1008-1009	,	_	_	
6-45	1010-1022	antioxidants	_	_	
6-46	1022-1023	,	_	_	
6-47	1024-1038	antimetabolite	_	_	
6-48	1039-1045	agents	_	_	
6-49	1045-1046	,	_	_	
6-50	1047-1050	and	_	_	
6-51	1051-1068	anti-inflammatory	_	_	
6-52	1069-1075	agents	_	_	
6-53	1076-1081	could	_	_	
6-54	1082-1084	be	_	_	
6-55	1085-1089	used	_	_	
6-56	1089-1090	.	_	_	

#Text=Antiplatelet agents can include drugs such as aspirin and dipyridamole.
7-1	1091-1103	Antiplatelet	_	_	
7-2	1104-1110	agents	_	_	
7-3	1111-1114	can	_	_	
7-4	1115-1122	include	_	_	
7-5	1123-1128	drugs	_	_	
7-6	1129-1133	such	_	_	
7-7	1134-1136	as	_	_	
7-8	1137-1144	aspirin	_	_	
7-9	1145-1148	and	_	_	
7-10	1149-1161	dipyridamole	_	_	
7-11	1161-1162	.	_	_	

#Text=Aspirin is classified as an analgesic, antipyretic, anti-inflammatory and antiplatelet drug.
8-1	1163-1170	Aspirin	_	_	
8-2	1171-1173	is	_	_	
8-3	1174-1184	classified	_	_	
8-4	1185-1187	as	_	_	
8-5	1188-1190	an	_	_	
8-6	1191-1200	analgesic	_	_	
8-7	1200-1201	,	_	_	
8-8	1202-1213	antipyretic	_	_	
8-9	1213-1214	,	_	_	
8-10	1215-1232	anti-inflammatory	_	_	
8-11	1233-1236	and	_	_	
8-12	1237-1249	antiplatelet	_	_	
8-13	1250-1254	drug	_	_	
8-14	1254-1255	.	_	_	

#Text=Dypridimole is a drug similar to aspirin in that it has anti-platelet characteristics.
9-1	1256-1267	Dypridimole	_	_	
9-2	1268-1270	is	_	_	
9-3	1271-1272	a	_	_	
9-4	1273-1277	drug	_	_	
9-5	1278-1285	similar	_	_	
9-6	1286-1288	to	_	_	
9-7	1289-1296	aspirin	_	_	
9-8	1297-1299	in	_	_	
9-9	1300-1304	that	_	_	
9-10	1305-1307	it	_	_	
9-11	1308-1311	has	_	_	
9-12	1312-1325	anti-platelet	_	_	
9-13	1326-1341	characteristics	_	_	
9-14	1341-1342	.	_	_	

#Text=Dypridimole is also classified as a coronary vasodilator.
10-1	1343-1354	Dypridimole	_	_	
10-2	1355-1357	is	_	_	
10-3	1358-1362	also	_	_	
10-4	1363-1373	classified	_	_	
10-5	1374-1376	as	_	_	
10-6	1377-1378	a	_	_	
10-7	1379-1387	coronary	_	_	
10-8	1388-1399	vasodilator	_	_	
10-9	1399-1400	.	_	_	

#Text=Anticoagulant agents can include drugs such as heparin, coumadin, protamine, hirudin and tick anticoagulant protein.
11-1	1401-1414	Anticoagulant	_	_	
11-2	1415-1421	agents	_	_	
11-3	1422-1425	can	_	_	
11-4	1426-1433	include	_	_	
11-5	1434-1439	drugs	_	_	
11-6	1440-1444	such	_	_	
11-7	1445-1447	as	_	_	
11-8	1448-1455	heparin	_	_	
11-9	1455-1456	,	_	_	
11-10	1457-1465	coumadin	_	_	
11-11	1465-1466	,	_	_	
11-12	1467-1476	protamine	_	_	
11-13	1476-1477	,	_	_	
11-14	1478-1485	hirudin	_	_	
11-15	1486-1489	and	_	_	
11-16	1490-1494	tick	_	_	
11-17	1495-1508	anticoagulant	_	_	
11-18	1509-1516	protein	_	_	
11-19	1516-1517	.	_	_	

#Text=Antimitotic agents and antimetabolite agents can include drugs such as methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin and mutamycin."
#Text=[0421] The precurors material may be one or more of the drugs disclosed in U.S.
12-1	1518-1529	Antimitotic	_	_	
12-2	1530-1536	agents	_	_	
12-3	1537-1540	and	_	_	
12-4	1541-1555	antimetabolite	_	_	
12-5	1556-1562	agents	_	_	
12-6	1563-1566	can	_	_	
12-7	1567-1574	include	_	_	
12-8	1575-1580	drugs	_	_	
12-9	1581-1585	such	_	_	
12-10	1586-1588	as	_	_	
12-11	1589-1601	methotrexate	_	_	
12-12	1601-1602	,	_	_	
12-13	1603-1615	azathioprine	_	_	
12-14	1615-1616	,	_	_	
12-15	1617-1628	vincristine	_	_	
12-16	1628-1629	,	_	_	
12-17	1630-1641	vinblastine	_	_	
12-18	1641-1642	,	_	_	
12-19	1643-1655	fluorouracil	_	_	
12-20	1655-1656	,	_	_	
12-21	1657-1667	adriamycin	_	_	
12-22	1668-1671	and	_	_	
12-23	1672-1681	mutamycin	_	_	
12-24	1681-1682	.	_	_	
12-25	1682-1683	"	_	_	
12-26	1684-1685	[	_	_	
12-27	1685-1689	0421	_	_	
12-28	1689-1690	]	_	_	
12-29	1691-1694	The	_	_	
12-30	1695-1704	precurors	_	_	
12-31	1705-1713	material	_	_	
12-32	1714-1717	may	_	_	
12-33	1718-1720	be	_	_	
12-34	1721-1724	one	_	_	
12-35	1725-1727	or	_	_	
12-36	1728-1732	more	_	_	
12-37	1733-1735	of	_	_	
12-38	1736-1739	the	_	_	
12-39	1740-1745	drugs	_	_	
12-40	1746-1755	disclosed	_	_	
12-41	1756-1758	in	_	_	
12-42	1759-1762	U.S	_	_	
12-43	1762-1763	.	_	_	

#Text=Pat.
13-1	1764-1767	Pat	_	_	
13-2	1767-1768	.	_	_	

#Text=No. 5,599,352, the entire disclosure of which is hereby incorporated by reference into this specification.
14-1	1769-1771	No	_	_	
14-2	1771-1772	.	_	_	
14-3	1773-1782	5,599,352	_	_	
14-4	1782-1783	,	_	_	
14-5	1784-1787	the	_	_	
14-6	1788-1794	entire	_	_	
14-7	1795-1805	disclosure	_	_	
14-8	1806-1808	of	_	_	
14-9	1809-1814	which	_	_	
14-10	1815-1817	is	_	_	
14-11	1818-1824	hereby	_	_	
14-12	1825-1837	incorporated	_	_	
14-13	1838-1840	by	_	_	
14-14	1841-1850	reference	_	_	
14-15	1851-1855	into	_	_	
14-16	1856-1860	this	_	_	
14-17	1861-1874	specification	_	_	
14-18	1874-1875	.	_	_	

#Text=As is disclosed in this patent, "Examples of drugs that are thought to be useful in the treatment of restenosis are disclosed in published international patent application WO 91/12779 "Intraluminal Drug Eluting Prosthesis" which is incorporated herein by reference.
15-1	1876-1878	As	_	_	
15-2	1879-1881	is	_	_	
15-3	1882-1891	disclosed	_	_	
15-4	1892-1894	in	_	_	
15-5	1895-1899	this	_	_	
15-6	1900-1906	patent	_	_	
15-7	1906-1907	,	_	_	
15-8	1908-1909	"	_	_	
15-9	1909-1917	Examples	_	_	
15-10	1918-1920	of	_	_	
15-11	1921-1926	drugs	_	_	
15-12	1927-1931	that	_	_	
15-13	1932-1935	are	_	_	
15-14	1936-1943	thought	_	_	
15-15	1944-1946	to	_	_	
15-16	1947-1949	be	_	_	
15-17	1950-1956	useful	_	_	
15-18	1957-1959	in	_	_	
15-19	1960-1963	the	_	_	
15-20	1964-1973	treatment	_	_	
15-21	1974-1976	of	_	_	
15-22	1977-1987	restenosis	_	_	
15-23	1988-1991	are	_	_	
15-24	1992-2001	disclosed	_	_	
15-25	2002-2004	in	_	_	
15-26	2005-2014	published	_	_	
15-27	2015-2028	international	_	_	
15-28	2029-2035	patent	_	_	
15-29	2036-2047	application	_	_	
15-30	2048-2050	WO	_	_	
15-31	2051-2053	91	_	_	
15-32	2053-2054	/	_	_	
15-33	2054-2059	12779	_	_	
15-34	2060-2061	"	_	_	
15-35	2061-2073	Intraluminal	_	_	
15-36	2074-2078	Drug	_	_	
15-37	2079-2086	Eluting	_	_	
15-38	2087-2097	Prosthesis	_	_	
15-39	2097-2098	"	_	_	
15-40	2099-2104	which	_	_	
15-41	2105-2107	is	_	_	
15-42	2108-2120	incorporated	_	_	
15-43	2121-2127	herein	_	_	
15-44	2128-2130	by	_	_	
15-45	2131-2140	reference	_	_	
15-46	2140-2141	.	_	_	

#Text=Therefore, useful drugs for treatment of restenosis and drugs that can be incorporated in the fibrin and used in the present invention can include drugs such as anticoagulant drugs, antiplatelet drugs, antimetabolite drugs, anti-inflammatory drugs and antimitotic drugs.
16-1	2142-2151	Therefore	*[1]	18-2[2_1]	
16-2	2151-2152	,	*[1]	_	
16-3	2153-2159	useful	*[1]	_	
16-4	2160-2165	drugs	*[1]	_	
16-5	2166-2169	for	*[1]	_	
16-6	2170-2179	treatment	*[1]	_	
16-7	2180-2182	of	*[1]	_	
16-8	2183-2193	restenosis	*[1]	_	
16-9	2194-2197	and	*[1]	_	
16-10	2198-2203	drugs	*[1]	_	
16-11	2204-2208	that	*[1]	_	
16-12	2209-2212	can	*[1]	_	
16-13	2213-2215	be	*[1]	_	
16-14	2216-2228	incorporated	*[1]	_	
16-15	2229-2231	in	*[1]	_	
16-16	2232-2235	the	*[1]	_	
16-17	2236-2242	fibrin	*[1]	_	
16-18	2243-2246	and	*[1]	_	
16-19	2247-2251	used	*[1]	_	
16-20	2252-2254	in	*[1]	_	
16-21	2255-2258	the	*[1]	_	
16-22	2259-2266	present	*[1]	_	
16-23	2267-2276	invention	*[1]	_	
16-24	2277-2280	can	*[1]	_	
16-25	2281-2288	include	*[1]	_	
16-26	2289-2294	drugs	*[1]	_	
16-27	2295-2299	such	*[1]	_	
16-28	2300-2302	as	*[1]	_	
16-29	2303-2316	anticoagulant	*[1]	_	
16-30	2317-2322	drugs	*[1]	_	
16-31	2322-2323	,	*[1]	_	
16-32	2324-2336	antiplatelet	*[1]	_	
16-33	2337-2342	drugs	*[1]	_	
16-34	2342-2343	,	*[1]	_	
16-35	2344-2358	antimetabolite	*[1]	_	
16-36	2359-2364	drugs	*[1]	_	
16-37	2364-2365	,	*[1]	_	
16-38	2366-2383	anti-inflammatory	*[1]	_	
16-39	2384-2389	drugs	*[1]	_	
16-40	2390-2393	and	*[1]	_	
16-41	2394-2405	antimitotic	*[1]	_	
16-42	2406-2411	drugs	*[1]	_	
16-43	2411-2412	.	*[1]	_	

#Text=Further, other vasoreactive agents such as nitric oxide releasing agents could also be used . . . .
17-1	2413-2420	Further	_	_	
17-2	2420-2421	,	_	_	
17-3	2422-2427	other	_	_	
17-4	2428-2440	vasoreactive	_	_	
17-5	2441-2447	agents	_	_	
17-6	2448-2452	such	_	_	
17-7	2453-2455	as	_	_	
17-8	2456-2462	nitric	_	_	
17-9	2463-2468	oxide	_	_	
17-10	2469-2478	releasing	_	_	
17-11	2479-2485	agents	_	_	
17-12	2486-2491	could	_	_	
17-13	2492-2496	also	_	_	
17-14	2497-2499	be	_	_	
17-15	2500-2504	used	_	_	
17-16	2505-2506	.	_	_	
17-17	2507-2508	.	_	_	
17-18	2509-2510	.	_	_	
17-19	2511-2512	.	_	_	

#Text=By this method, drugs such as glucocorticoids (e.g. dexamethasone, betamethasone), heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, and, more generally, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents can be applied to a stent . . . ."
#Text=[0422] By way of yet further illustration, and referring to U.S.
18-1	2513-2515	By	_	_	
18-2	2516-2520	this	*[2]	_	
18-3	2521-2527	method	*[2]	_	
18-4	2527-2528	,	_	_	
18-5	2529-2534	drugs	_	_	
18-6	2535-2539	such	_	_	
18-7	2540-2542	as	_	_	
18-8	2543-2558	glucocorticoids	_	_	
18-9	2559-2560	(	_	_	
18-10	2560-2563	e.g	_	_	
18-11	2563-2564	.	_	_	
18-12	2565-2578	dexamethasone	_	_	
18-13	2578-2579	,	_	_	
18-14	2580-2593	betamethasone	_	_	
18-15	2593-2594	)	_	_	
18-16	2594-2595	,	_	_	
18-17	2596-2603	heparin	_	_	
18-18	2603-2604	,	_	_	
18-19	2605-2612	hirudin	_	_	
18-20	2612-2613	,	_	_	
18-21	2614-2624	tocopherol	_	_	
18-22	2624-2625	,	_	_	
18-23	2626-2637	angiopeptin	_	_	
18-24	2637-2638	,	_	_	
18-25	2639-2646	aspirin	_	_	
18-26	2646-2647	,	_	_	
18-27	2648-2651	ACE	_	_	
18-28	2652-2662	inhibitors	_	_	
18-29	2662-2663	,	_	_	
18-30	2664-2670	growth	_	_	
18-31	2671-2678	factors	_	_	
18-32	2678-2679	,	_	_	
18-33	2680-2696	oligonucleotides	_	_	
18-34	2696-2697	,	_	_	
18-35	2698-2701	and	_	_	
18-36	2701-2702	,	_	_	
18-37	2703-2707	more	_	_	
18-38	2708-2717	generally	_	_	
18-39	2717-2718	,	_	_	
18-40	2719-2731	antiplatelet	_	_	
18-41	2732-2738	agents	_	_	
18-42	2738-2739	,	_	_	
18-43	2740-2753	anticoagulant	_	_	
18-44	2754-2760	agents	_	_	
18-45	2760-2761	,	_	_	
18-46	2762-2773	antimitotic	_	_	
18-47	2774-2780	agents	_	_	
18-48	2780-2781	,	_	_	
18-49	2782-2794	antioxidants	_	_	
18-50	2794-2795	,	_	_	
18-51	2796-2810	antimetabolite	_	_	
18-52	2811-2817	agents	_	_	
18-53	2817-2818	,	_	_	
18-54	2819-2822	and	_	_	
18-55	2823-2840	anti-inflammatory	_	_	
18-56	2841-2847	agents	_	_	
18-57	2848-2851	can	_	_	
18-58	2852-2854	be	_	_	
18-59	2855-2862	applied	_	_	
18-60	2863-2865	to	_	_	
18-61	2866-2867	a	_	_	
18-62	2868-2873	stent	_	_	
18-63	2874-2875	.	_	_	
18-64	2876-2877	.	_	_	
18-65	2878-2879	.	_	_	
18-66	2880-2881	.	_	_	
18-67	2881-2882	"	_	_	
18-68	2883-2884	[	_	_	
18-69	2884-2888	0422	_	_	
18-70	2888-2889	]	_	_	
18-71	2890-2892	By	_	_	
18-72	2893-2896	way	_	_	
18-73	2897-2899	of	_	_	
18-74	2900-2903	yet	_	_	
18-75	2904-2911	further	_	_	
18-76	2912-2924	illustration	_	_	
18-77	2924-2925	,	_	_	
18-78	2926-2929	and	_	_	
18-79	2930-2939	referring	_	_	
18-80	2940-2942	to	_	_	
18-81	2943-2946	U.S	_	_	
18-82	2946-2947	.	_	_	

#Text=Pat.
19-1	2948-2951	Pat	_	_	
19-2	2951-2952	.	_	_	

#Text=No. 5,605,696 (the entire disclosure of which is hereby incororporated by reference into this specification), the precursor may be a "selected therapeutic drug" that may be, e.g., " . . . anticoagulant antiplatelet or antithrombin agents such as heparin, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, hirudin, recombinant hirudin, thrombin inhibitor (available from Biogen), or c7E3 (an antiplatelet drug from Centocore); cytostatic or antiproliferative agents such as angiopeptin (a somatostatin analogue from Ibsen), angiotensin converting enzyme inhibitors such as Captopril (available from Squibb), Cilazapril (available from Hoffman-LaRoche), or Lisinopril (available from Merk); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), low molecular weight heparin (available from Wyeth, and Glycomed), histamine antagonists, Lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merk), methotrexate, monoclonal antibodies (such as to PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostacyclin and prostacyclin analogues, prostaglandin inhibitor (available from Glaxo), Seramin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, and triazolopyrimidine (a PDGF antagonist).
20-1	2953-2955	No	_	_	
20-2	2955-2956	.	_	_	
20-3	2957-2966	5,605,696	_	_	
20-4	2967-2968	(	_	_	
20-5	2968-2971	the	_	_	
20-6	2972-2978	entire	_	_	
20-7	2979-2989	disclosure	_	_	
20-8	2990-2992	of	_	_	
20-9	2993-2998	which	_	_	
20-10	2999-3001	is	_	_	
20-11	3002-3008	hereby	_	_	
20-12	3009-3023	incororporated	_	_	
20-13	3024-3026	by	_	_	
20-14	3027-3036	reference	_	_	
20-15	3037-3041	into	_	_	
20-16	3042-3046	this	_	_	
20-17	3047-3060	specification	_	_	
20-18	3060-3061	)	_	_	
20-19	3061-3062	,	_	_	
20-20	3063-3066	the	_	_	
20-21	3067-3076	precursor	_	_	
20-22	3077-3080	may	_	_	
20-23	3081-3083	be	_	_	
20-24	3084-3085	a	_	_	
20-25	3086-3087	"	_	_	
20-26	3087-3095	selected	_	_	
20-27	3096-3107	therapeutic	_	_	
20-28	3108-3112	drug	_	_	
20-29	3112-3113	"	_	_	
20-30	3114-3118	that	_	_	
20-31	3119-3122	may	_	_	
20-32	3123-3125	be	_	_	
20-33	3125-3126	,	_	_	
20-34	3127-3130	e.g	_	_	
20-35	3130-3131	.	_	_	
20-36	3131-3132	,	_	_	
20-37	3133-3134	"	_	_	
20-38	3135-3136	.	_	_	
20-39	3137-3138	.	_	_	
20-40	3139-3140	.	_	_	
20-41	3141-3154	anticoagulant	_	_	
20-42	3155-3167	antiplatelet	_	_	
20-43	3168-3170	or	_	_	
20-44	3171-3183	antithrombin	_	_	
20-45	3184-3190	agents	_	_	
20-46	3191-3195	such	_	_	
20-47	3196-3198	as	_	_	
20-48	3199-3206	heparin	_	_	
20-49	3206-3207	,	_	_	
20-50	3208-3240	D-phe-pro-arg-chloromethylketone	_	_	
20-51	3241-3242	(	_	_	
20-52	3242-3251	synthetic	_	_	
20-53	3252-3264	antithrombin	_	_	
20-54	3264-3265	)	_	_	
20-55	3265-3266	,	_	_	
20-56	3267-3279	dipyridamole	_	_	
20-57	3279-3280	,	_	_	
20-58	3281-3288	hirudin	_	_	
20-59	3288-3289	,	_	_	
20-60	3290-3301	recombinant	_	_	
20-61	3302-3309	hirudin	_	_	
20-62	3309-3310	,	_	_	
20-63	3311-3319	thrombin	_	_	
20-64	3320-3329	inhibitor	_	_	
20-65	3330-3331	(	_	_	
20-66	3331-3340	available	_	_	
20-67	3341-3345	from	_	_	
20-68	3346-3352	Biogen	_	_	
20-69	3352-3353	)	_	_	
20-70	3353-3354	,	_	_	
20-71	3355-3357	or	_	_	
20-72	3358-3362	c7E3	_	_	
20-73	3363-3364	(	_	_	
20-74	3364-3366	an	_	_	
20-75	3367-3379	antiplatelet	_	_	
20-76	3380-3384	drug	_	_	
20-77	3385-3389	from	_	_	
20-78	3390-3399	Centocore	_	_	
20-79	3399-3400	)	_	_	
20-80	3400-3401	;	_	_	
20-81	3402-3412	cytostatic	_	_	
20-82	3413-3415	or	_	_	
20-83	3416-3433	antiproliferative	_	_	
20-84	3434-3440	agents	_	_	
20-85	3441-3445	such	_	_	
20-86	3446-3448	as	_	_	
20-87	3449-3460	angiopeptin	_	_	
20-88	3461-3462	(	_	_	
20-89	3462-3463	a	_	_	
20-90	3464-3476	somatostatin	_	_	
20-91	3477-3485	analogue	_	_	
20-92	3486-3490	from	_	_	
20-93	3491-3496	Ibsen	_	_	
20-94	3496-3497	)	_	_	
20-95	3497-3498	,	_	_	
20-96	3499-3510	angiotensin	_	_	
20-97	3511-3521	converting	_	_	
20-98	3522-3528	enzyme	_	_	
20-99	3529-3539	inhibitors	_	_	
20-100	3540-3544	such	_	_	
20-101	3545-3547	as	_	_	
20-102	3548-3557	Captopril	_	_	
20-103	3558-3559	(	_	_	
20-104	3559-3568	available	_	_	
20-105	3569-3573	from	_	_	
20-106	3574-3580	Squibb	_	_	
20-107	3580-3581	)	_	_	
20-108	3581-3582	,	_	_	
20-109	3583-3593	Cilazapril	_	_	
20-110	3594-3595	(	_	_	
20-111	3595-3604	available	_	_	
20-112	3605-3609	from	_	_	
20-113	3610-3625	Hoffman-LaRoche	_	_	
20-114	3625-3626	)	_	_	
20-115	3626-3627	,	_	_	
20-116	3628-3630	or	_	_	
20-117	3631-3641	Lisinopril	_	_	
20-118	3642-3643	(	_	_	
20-119	3643-3652	available	_	_	
20-120	3653-3657	from	_	_	
20-121	3658-3662	Merk	_	_	
20-122	3662-3663	)	_	_	
20-123	3663-3664	;	_	_	
20-124	3665-3672	calcium	_	_	
20-125	3673-3680	channel	_	_	
20-126	3681-3689	blockers	_	_	
20-127	3690-3691	(	_	_	
20-128	3691-3695	such	_	_	
20-129	3696-3698	as	_	_	
20-130	3699-3709	Nifedipine	_	_	
20-131	3709-3710	)	_	_	
20-132	3710-3711	,	_	_	
20-133	3712-3722	colchicine	_	_	
20-134	3722-3723	,	_	_	
20-135	3724-3734	fibroblast	_	_	
20-136	3735-3741	growth	_	_	
20-137	3742-3748	factor	_	_	
20-138	3749-3750	(	_	_	
20-139	3750-3753	FGF	_	_	
20-140	3753-3754	)	_	_	
20-141	3755-3766	antagonists	_	_	
20-142	3766-3767	,	_	_	
20-143	3768-3772	fish	_	_	
20-144	3773-3776	oil	_	_	
20-145	3777-3778	(	_	_	
20-146	3778-3783	omega	_	_	
20-147	3784-3785	3	_	_	
20-148	3785-3786	-	_	_	
20-149	3786-3791	fatty	_	_	
20-150	3792-3796	acid	_	_	
20-151	3796-3797	)	_	_	
20-152	3797-3798	,	_	_	
20-153	3799-3802	low	_	_	
20-154	3803-3812	molecular	_	_	
20-155	3813-3819	weight	_	_	
20-156	3820-3827	heparin	_	_	
20-157	3828-3829	(	_	_	
20-158	3829-3838	available	_	_	
20-159	3839-3843	from	_	_	
20-160	3844-3849	Wyeth	_	_	
20-161	3849-3850	,	_	_	
20-162	3851-3854	and	_	_	
20-163	3855-3863	Glycomed	_	_	
20-164	3863-3864	)	_	_	
20-165	3864-3865	,	_	_	
20-166	3866-3875	histamine	_	_	
20-167	3876-3887	antagonists	_	_	
20-168	3887-3888	,	_	_	
20-169	3889-3899	Lovastatin	_	_	
20-170	3900-3901	(	_	_	
20-171	3901-3903	an	_	_	
20-172	3904-3913	inhibitor	_	_	
20-173	3914-3916	of	_	_	
20-174	3917-3924	HMG-CoA	_	_	
20-175	3925-3934	reductase	_	_	
20-176	3934-3935	,	_	_	
20-177	3936-3937	a	_	_	
20-178	3938-3949	cholesterol	_	_	
20-179	3950-3958	lowering	_	_	
20-180	3959-3963	drug	_	_	
20-181	3964-3968	from	_	_	
20-182	3969-3973	Merk	_	_	
20-183	3973-3974	)	_	_	
20-184	3974-3975	,	_	_	
20-185	3976-3988	methotrexate	_	_	
20-186	3988-3989	,	_	_	
20-187	3990-4000	monoclonal	_	_	
20-188	4001-4011	antibodies	_	_	
20-189	4012-4013	(	_	_	
20-190	4013-4017	such	_	_	
20-191	4018-4020	as	_	_	
20-192	4021-4023	to	_	_	
20-193	4024-4028	PDGF	_	_	
20-194	4029-4038	receptors	_	_	
20-195	4038-4039	)	_	_	
20-196	4039-4040	,	_	_	
20-197	4041-4054	nitroprusside	_	_	
20-198	4054-4055	,	_	_	
20-199	4056-4073	phosphodiesterase	_	_	
20-200	4074-4084	inhibitors	_	_	
20-201	4084-4085	,	_	_	
20-202	4086-4098	prostacyclin	_	_	
20-203	4099-4102	and	_	_	
20-204	4103-4115	prostacyclin	_	_	
20-205	4116-4125	analogues	_	_	
20-206	4125-4126	,	_	_	
20-207	4127-4140	prostaglandin	_	_	
20-208	4141-4150	inhibitor	_	_	
20-209	4151-4152	(	_	_	
20-210	4152-4161	available	_	_	
20-211	4162-4166	from	_	_	
20-212	4167-4172	Glaxo	_	_	
20-213	4172-4173	)	_	_	
20-214	4173-4174	,	_	_	
20-215	4175-4182	Seramin	_	_	
20-216	4183-4184	(	_	_	
20-217	4184-4185	a	_	_	
20-218	4186-4190	PDGF	_	_	
20-219	4191-4201	antagonist	_	_	
20-220	4201-4202	)	_	_	
20-221	4202-4203	,	_	_	
20-222	4204-4213	serotonin	_	_	
20-223	4214-4222	blockers	_	_	
20-224	4222-4223	,	_	_	
20-225	4224-4232	steroids	_	_	
20-226	4232-4233	,	_	_	
20-227	4234-4246	thioprotease	_	_	
20-228	4247-4257	inhibitors	_	_	
20-229	4257-4258	,	_	_	
20-230	4259-4262	and	_	_	
20-231	4263-4281	triazolopyrimidine	_	_	
20-232	4282-4283	(	_	_	
20-233	4283-4284	a	_	_	
20-234	4285-4289	PDGF	_	_	
20-235	4290-4300	antagonist	_	_	
20-236	4300-4301	)	_	_	
20-237	4301-4302	.	_	_	

#Text=Other therapeutic drugs which may be appropriate include alphainterferon and genetically engineered epithelial cells, for example."
#Text=[0423] By way of yet further illustration, and referring to U.S.
21-1	4303-4308	Other	_	_	
21-2	4309-4320	therapeutic	_	_	
21-3	4321-4326	drugs	_	_	
21-4	4327-4332	which	_	_	
21-5	4333-4336	may	_	_	
21-6	4337-4339	be	_	_	
21-7	4340-4351	appropriate	_	_	
21-8	4352-4359	include	_	_	
21-9	4360-4375	alphainterferon	_	_	
21-10	4376-4379	and	_	_	
21-11	4380-4391	genetically	_	_	
21-12	4392-4402	engineered	_	_	
21-13	4403-4413	epithelial	_	_	
21-14	4414-4419	cells	_	_	
21-15	4419-4420	,	_	_	
21-16	4421-4424	for	_	_	
21-17	4425-4432	example	_	_	
21-18	4432-4433	.	_	_	
21-19	4433-4434	"	_	_	
21-20	4435-4436	[	_	_	
21-21	4436-4440	0423	_	_	
21-22	4440-4441	]	_	_	
21-23	4442-4444	By	_	_	
21-24	4445-4448	way	_	_	
21-25	4449-4451	of	_	_	
21-26	4452-4455	yet	_	_	
21-27	4456-4463	further	_	_	
21-28	4464-4476	illustration	_	_	
21-29	4476-4477	,	_	_	
21-30	4478-4481	and	_	_	
21-31	4482-4491	referring	_	_	
21-32	4492-4494	to	_	_	
21-33	4495-4498	U.S	_	_	
21-34	4498-4499	.	_	_	

#Text=Pat.
22-1	4500-4503	Pat	_	_	
22-2	4503-4504	.	_	_	

#Text=No. 5,700,286 (the entire disclosure of which is hereby incorporated by reference into this specification), precursor material may be a therapeutic agent or drug " . . . including, but not limited to, antiplatelets, antithrombins, cytostatic and antiproliferative agents, for example, to reduce or prevent restenosis in the vessel being treated.
23-1	4505-4507	No	_	_	
23-2	4507-4508	.	_	_	
23-3	4509-4518	5,700,286	_	_	
23-4	4519-4520	(	_	_	
23-5	4520-4523	the	_	_	
23-6	4524-4530	entire	_	_	
23-7	4531-4541	disclosure	_	_	
23-8	4542-4544	of	_	_	
23-9	4545-4550	which	_	_	
23-10	4551-4553	is	_	_	
23-11	4554-4560	hereby	_	_	
23-12	4561-4573	incorporated	_	_	
23-13	4574-4576	by	_	_	
23-14	4577-4586	reference	_	_	
23-15	4587-4591	into	_	_	
23-16	4592-4596	this	_	_	
23-17	4597-4610	specification	_	_	
23-18	4610-4611	)	_	_	
23-19	4611-4612	,	_	_	
23-20	4613-4622	precursor	_	_	
23-21	4623-4631	material	_	_	
23-22	4632-4635	may	_	_	
23-23	4636-4638	be	_	_	
23-24	4639-4640	a	_	_	
23-25	4641-4652	therapeutic	_	_	
23-26	4653-4658	agent	_	_	
23-27	4659-4661	or	_	_	
23-28	4662-4666	drug	_	_	
23-29	4667-4668	"	_	_	
23-30	4669-4670	.	_	_	
23-31	4671-4672	.	_	_	
23-32	4673-4674	.	_	_	
23-33	4675-4684	including	_	_	
23-34	4684-4685	,	_	_	
23-35	4686-4689	but	_	_	
23-36	4690-4693	not	_	_	
23-37	4694-4701	limited	_	_	
23-38	4702-4704	to	_	_	
23-39	4704-4705	,	_	_	
23-40	4706-4719	antiplatelets	_	_	
23-41	4719-4720	,	_	_	
23-42	4721-4734	antithrombins	_	_	
23-43	4734-4735	,	_	_	
23-44	4736-4746	cytostatic	_	_	
23-45	4747-4750	and	_	_	
23-46	4751-4768	antiproliferative	_	_	
23-47	4769-4775	agents	_	_	
23-48	4775-4776	,	_	_	
23-49	4777-4780	for	_	_	
23-50	4781-4788	example	_	_	
23-51	4788-4789	,	_	_	
23-52	4790-4792	to	_	_	
23-53	4793-4799	reduce	_	_	
23-54	4800-4802	or	_	_	
23-55	4803-4810	prevent	_	_	
23-56	4811-4821	restenosis	_	_	
23-57	4822-4824	in	_	_	
23-58	4825-4828	the	_	_	
23-59	4829-4835	vessel	_	_	
23-60	4836-4841	being	_	_	
23-61	4842-4849	treated	_	_	
23-62	4849-4850	.	_	_	

#Text=The therapeutic agent or drug is preferably selected from the group of therapeutic agents or drugs consisting of sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antibody, recombinant hirudin, thrombin inhibitor, angiopeptin, angiotensin converting enzyme inhibitors, (such as Captopril, available from Squibb; Cilazapril, available for Hoffman-La Roche; or Lisinopril, available from Merck) calcium channel blockers, colchicine, fibroblast growth factor antagonists, fish oil, omega 3-fatty acid, histamine antagonists, HMG-CoA reductase inhibitor, methotrexate, monoclonal antibodies, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor, seramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine and other PDGF antagonists, alpha-interferon and genetically engineered epithelial cells, and combinations thereof."
24-1	4851-4854	The	_	_	
24-2	4855-4866	therapeutic	_	_	
24-3	4867-4872	agent	_	_	
24-4	4873-4875	or	_	_	
24-5	4876-4880	drug	_	_	
24-6	4881-4883	is	_	_	
24-7	4884-4894	preferably	_	_	
24-8	4895-4903	selected	_	_	
24-9	4904-4908	from	_	_	
24-10	4909-4912	the	_	_	
24-11	4913-4918	group	_	_	
24-12	4919-4921	of	_	_	
24-13	4922-4933	therapeutic	_	_	
24-14	4934-4940	agents	_	_	
24-15	4941-4943	or	_	_	
24-16	4944-4949	drugs	_	_	
24-17	4950-4960	consisting	_	_	
24-18	4961-4963	of	_	_	
24-19	4964-4970	sodium	_	_	
24-20	4971-4978	heparin	_	_	
24-21	4978-4979	,	_	_	
24-22	4980-4983	low	_	_	
24-23	4984-4993	molecular	_	_	
24-24	4994-5000	weight	_	_	
24-25	5001-5008	heparin	_	_	
24-26	5008-5009	,	_	_	
24-27	5010-5017	hirudin	_	_	
24-28	5017-5018	,	_	_	
24-29	5019-5029	argatroban	_	_	
24-30	5029-5030	,	_	_	
24-31	5031-5040	forskolin	_	_	
24-32	5040-5041	,	_	_	
24-33	5042-5051	vapiprost	_	_	
24-34	5051-5052	,	_	_	
24-35	5053-5065	prostacyclin	_	_	
24-36	5066-5069	and	_	_	
24-37	5070-5082	prostacyclin	_	_	
24-38	5083-5092	analogues	_	_	
24-39	5092-5093	,	_	_	
24-40	5094-5101	dextran	_	_	
24-41	5101-5102	,	_	_	
24-42	5103-5135	D-phe-pro-arg-chloromethylketone	_	_	
24-43	5135-5136	,	_	_	
24-44	5137-5149	dipyridamole	_	_	
24-45	5149-5150	,	_	_	
24-46	5151-5163	glycoprotein	_	_	
24-47	5164-5167	IIb	_	_	
24-48	5167-5168	/	_	_	
24-49	5168-5172	IIIa	_	_	
24-50	5173-5181	platelet	_	_	
24-51	5182-5190	membrane	_	_	
24-52	5191-5199	receptor	_	_	
24-53	5200-5208	antibody	_	_	
24-54	5208-5209	,	_	_	
24-55	5210-5221	recombinant	_	_	
24-56	5222-5229	hirudin	_	_	
24-57	5229-5230	,	_	_	
24-58	5231-5239	thrombin	_	_	
24-59	5240-5249	inhibitor	_	_	
24-60	5249-5250	,	_	_	
24-61	5251-5262	angiopeptin	_	_	
24-62	5262-5263	,	_	_	
24-63	5264-5275	angiotensin	_	_	
24-64	5276-5286	converting	_	_	
24-65	5287-5293	enzyme	_	_	
24-66	5294-5304	inhibitors	_	_	
24-67	5304-5305	,	_	_	
24-68	5306-5307	(	_	_	
24-69	5307-5311	such	_	_	
24-70	5312-5314	as	_	_	
24-71	5315-5324	Captopril	_	_	
24-72	5324-5325	,	_	_	
24-73	5326-5335	available	_	_	
24-74	5336-5340	from	_	_	
24-75	5341-5347	Squibb	_	_	
24-76	5347-5348	;	_	_	
24-77	5349-5359	Cilazapril	_	_	
24-78	5359-5360	,	_	_	
24-79	5361-5370	available	_	_	
24-80	5371-5374	for	_	_	
24-81	5375-5385	Hoffman-La	_	_	
24-82	5386-5391	Roche	_	_	
24-83	5391-5392	;	_	_	
24-84	5393-5395	or	_	_	
24-85	5396-5406	Lisinopril	_	_	
24-86	5406-5407	,	_	_	
24-87	5408-5417	available	_	_	
24-88	5418-5422	from	_	_	
24-89	5423-5428	Merck	_	_	
24-90	5428-5429	)	_	_	
24-91	5430-5437	calcium	_	_	
24-92	5438-5445	channel	_	_	
24-93	5446-5454	blockers	_	_	
24-94	5454-5455	,	_	_	
24-95	5456-5466	colchicine	_	_	
24-96	5466-5467	,	_	_	
24-97	5468-5478	fibroblast	_	_	
24-98	5479-5485	growth	_	_	
24-99	5486-5492	factor	_	_	
24-100	5493-5504	antagonists	_	_	
24-101	5504-5505	,	_	_	
24-102	5506-5510	fish	_	_	
24-103	5511-5514	oil	_	_	
24-104	5514-5515	,	_	_	
24-105	5516-5521	omega	_	_	
24-106	5522-5523	3	_	_	
24-107	5523-5524	-	_	_	
24-108	5524-5529	fatty	_	_	
24-109	5530-5534	acid	_	_	
24-110	5534-5535	,	_	_	
24-111	5536-5545	histamine	_	_	
24-112	5546-5557	antagonists	_	_	
24-113	5557-5558	,	_	_	
24-114	5559-5566	HMG-CoA	_	_	
24-115	5567-5576	reductase	_	_	
24-116	5577-5586	inhibitor	_	_	
24-117	5586-5587	,	_	_	
24-118	5588-5600	methotrexate	_	_	
24-119	5600-5601	,	_	_	
24-120	5602-5612	monoclonal	_	_	
24-121	5613-5623	antibodies	_	_	
24-122	5623-5624	,	_	_	
24-123	5625-5638	nitroprusside	_	_	
24-124	5638-5639	,	_	_	
24-125	5640-5657	phosphodiesterase	_	_	
24-126	5658-5668	inhibitors	_	_	
24-127	5668-5669	,	_	_	
24-128	5670-5683	prostaglandin	_	_	
24-129	5684-5693	inhibitor	_	_	
24-130	5693-5694	,	_	_	
24-131	5695-5702	seramin	_	_	
24-132	5702-5703	,	_	_	
24-133	5704-5713	serotonin	_	_	
24-134	5714-5722	blockers	_	_	
24-135	5722-5723	,	_	_	
24-136	5724-5732	steroids	_	_	
24-137	5732-5733	,	_	_	
24-138	5734-5746	thioprotease	_	_	
24-139	5747-5757	inhibitors	_	_	
24-140	5757-5758	,	_	_	
24-141	5759-5777	triazolopyrimidine	_	_	
24-142	5778-5781	and	_	_	
24-143	5782-5787	other	_	_	
24-144	5788-5792	PDGF	_	_	
24-145	5793-5804	antagonists	_	_	
24-146	5804-5805	,	_	_	
24-147	5806-5822	alpha-interferon	_	_	
24-148	5823-5826	and	_	_	
24-149	5827-5838	genetically	_	_	
24-150	5839-5849	engineered	_	_	
24-151	5850-5860	epithelial	_	_	
24-152	5861-5866	cells	_	_	
24-153	5866-5867	,	_	_	
24-154	5868-5871	and	_	_	
24-155	5872-5884	combinations	_	_	
24-156	5885-5892	thereof	_	_	
24-157	5892-5893	.	_	_	
24-158	5893-5894	"	_	_	
